AstraZeneca’s Symbicort inhalation aerosol has demonstrated safety and efficacy results in African-American patients with moderate-to-severe persistent asthma.
Symbicort is a combination asthma medication that contains both an inhaled corticosteroid (budesonide) and a long-acting beta-agonist (formoterol).
The 52-week, randomised and double-blind Phase III study included 742 self-reported African-American patients. It showed that patients in the Symbicort group had fewer exacerbations compared to patients treated with a budesonide pressurised metred-dose inhaler.
Treatment with the inhalation aerosol also resulted in improvements in pre-dose forced expiratory volume in one second, pre-dose forced vital capacity and morning peak expiratory flow.
AstraZeneca clinical research director Ubaldo Martin said the data from the Symbicort study supports the understanding of the product’s efficacy and safety in African-American patients, who are more prone to asthma.
The adverse events observed with the use of Symbicort or budesonide were headache, nasopharyngitis, sinusitis and viral upper respiratory tract infection.